Signaling and molecular basis of bone marrow niche angiogenesis in leukemia

被引:0
作者
R. Shirzad
S. Shahrabi
A. Ahmadzadeh
K. R. Kampen
M. Shahjahani
N. Saki
机构
[1] Ahvaz Jundishapur University of Medical Sciences,Health Research Institute, Thalassemia and Hemoglobinopathies Research Center
[2] Semnan University of Medical Sciences,Department of Biochemistry and Hematology, Faculty of Medicine
[3] University Medical Center Groningen,Department of Pediatric Oncology/Hematology, Beatrix Children’s Hospital
[4] University of Groningen,undefined
来源
Clinical and Translational Oncology | 2016年 / 18卷
关键词
Bone marrow; Niche; Leukemia; Angiogenesis; Drug resistance; miR;
D O I
暂无
中图分类号
学科分类号
摘要
Angiogenesis, the process of blood vessel formation, is necessary for tissue survival in normal and pathologic conditions. Increased angiogenesis in BM niche is correlated with leukemia progression and resistance to treatment. Angiogenesis can interfere with disease progression and several angiogenic (such as vascular growth factors) as well as anti-angiogenic factors (i.e. angiostatin) can affect angiogenesis. Furthermore, miRs can affect the angiogenic process by inhibiting angiogenesis or increasing the expression of growth factors. Given the importance of angiogenesis in BM for maintenance of leukemic clones, recognition of angiogenic and anti-angiogenic factors and miRs as well as drug resistance mechanisms of leukemic blasts can improve the therapeutic strategies. We highlight the changes in angiogenic balance within the BM niche in different leukemia types. Moreover, we explored the pathways leading to drug resistance in relation to angiogenesis and attempted to assign interesting candidates for future research.
引用
收藏
页码:957 / 971
页数:14
相关论文
共 255 条
[1]  
Nwajei F(2013)The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells Adv Hematol 2013 8-1441
[2]  
Konopleva M(2011)Osteoblastic and vascular endothelial niches, their control on normal hematopoietic stem cells, and their consequences on the development of leukemia Stem Cells Int 2011 8-1234
[3]  
Guerrouahen BS(2001)Regulation of the acute myeloid leukemia cell line OCI/AML-2 by endothelial nitric oxide synthase under the control of a vascular endothelial growth factor signaling system Leukemia 15 1433-1190
[4]  
Al-Hijji I(2003)Antiangiogenic therapy in hematologic malignancies Curr Pharm Des 10 1221-611
[5]  
Tabrizi AR(2004)Bone marrow microvessel density (MVD) in adult acute myeloid leukemia (AML): therapy induced changes and effects on survival Leuk Lymphoma 45 1185-610
[6]  
Koistinen P(2008)Stem cells and niches: mechanisms that promote stem cell maintenance throughout life Cell 132 598-3351
[7]  
Siitonen T(1999)Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia Br J Haematol 107 605-46
[8]  
Mäntymaa P(2002)Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia Blood 100 3344-1572
[9]  
Säily M(2005)Circulating vascular endothelial growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia Eur Cytokine Netw 16 41-1063
[10]  
Kinnula V(2008)Bone marrow fibroblasts induce expression of PI3 K/NF-κB pathway genes and a pro-angiogenic phenotype in CLL cells Leuk Res 32 1565-2993